Olodaterol

Olodaterol

Clinical data
Trade names	Striverdi Respimat
AHFS/Drugs.com	UK Drug Information
Pregnancy category	US: C (Risk not ruled out) No experience
Routes of administration	Inhalation (MDI)
ATC code	R03AC19 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	~30% (inhalation)
Protein binding	~60%
Metabolism	Hepatic
Biological half-life	7.5 hours
Excretion	Feces (53%), urine (38%) — following IV administration
Identifiers
IUPAC name 6-hydroxy-8-{(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl}-4H-1,4-benzoxazin-3-one
Synonyms	BI 1744 CL
CAS Number	868049-49-4
PubChem CID	11504295
IUPHAR/BPS	7543
ChemSpider	9679097
UNII	VD2YSN1AFD
KEGG	D10145
ChEBI	CHEBI:82700 Y
ChEMBL	CHEMBL605846
Chemical and physical data
Formula	C21H26N2O5
Molar mass	386.44 g/mol
3D model (Jmol)	Interactive image
SMILES CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=CC(=CC3=C2OCC(=O)N3)O)O
InChI InChI=1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1 Key:COUYJEVMBVSIHV-SFHVURJKSA-N

Olodaterol (trade name Striverdi Respimat STRIH-ver-dee-RES-peh-mat) is an ultra-long-acting β adrenoreceptor agonist (ultra-LABA) used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD), manufactured by Boehringer Ingelheim.

Olodaterol is a once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD including chronic bronchitis and/or emphysema, and is administered in an inhaler called Respimat Soft Mist Inhaler.

As of December 2013^[update], olodaterol is not approved for the treatment of asthma. Olodaterol monotherapy was previously evaluated in four Phase II studies in asthma patients. However, currently there are no Phase III studies planned for olodaterol monotherapy in patients with asthma.

Adverse effects generally were rare and mild in clinical studies. Most common, but still affecting no more than 1% of patients, were nasopharyngitis (running nose), dizziness and rash. To judge from the drug's mechanism of action and from experiences with related drugs, hypertension (high blood pressure), tachycardia (fast heartbeat), hypokalemia (low blood levels of potassium), shaking, etc., might occur in some patients, but these effects have rarely, if at all, been observed in studies.